Obsessive Compulsive Disorder- Pipeline Insight, 2025

This “Obsessive Compulsive Disorder- Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Obsessive Compulsive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Obsessive Compulsive Disorder Understanding

Obsessive Compulsive Disorder: Overview

Obsessive-Compulsive Disorder (OCD) is a common, chronic, and long-lasting disorder in which a person has uncontrollable, reoccurring thoughts (obsessions) and/or behaviors (compulsions) that he or she feels the urge to repeat over and over. People with OCD may have symptoms of obsessions, compulsions, or both. These symptoms can interfere with all aspects of life, such as work, school, and personal relationships. But a person with OCD generally: Can't control his or her thoughts or behaviors, even when those thoughts or behaviors are recognized as excessive, spends at least 1 hour a day on these thoughts or behaviors, doesn’t get pleasure when performing the behaviors or rituals, but may feel brief relief from the anxiety the thoughts cause, experiences significant problems in their daily life due to these thoughts or behaviors. Some individuals with OCD also have a tic disorder. People with OCD may try to help themselves by avoiding situations that trigger their obsessions, or they may use alcohol or drugs to calm themselves. Although most adults with OCD recognize that what they are doing doesn’t make sense, some adults and most children may not realize that their behavior is out of the ordinary. Parents or teachers typically recognize OCD symptoms in children. OCD is a common disorder that affects adults, adolescents, and children all over the world. Most people are diagnosed by about age 19, typically with an earlier age of onset in boys than in girls, but onset after age 35 does happen. OCD is typically treated with medication, psychotherapy, or a combination of the two. Although most patients with OCD respond to treatment, some patients continue to experience symptoms. Sometimes people with OCD also have other mental disorders, such as anxiety, depression, and body dysmorphic disorder, a disorder in which someone mistakenly believes that a part of their body is abnormal. It is important to consider these other disorders when making decisions about treatment.

'Obsessive Compulsive Disorder- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obsessive Compulsive Disorder pipeline landscape is provided which includes the disease overview and Obsessive Compulsive Disorder treatment guidelines. The assessment part of the report embraces, in depth Obsessive Compulsive Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obsessive Compulsive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Obsessive Compulsive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Obsessive Compulsive Disorder.

Obsessive Compulsive Disorder Emerging Drugs Chapters

This segment of the Obsessive Compulsive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obsessive Compulsive Disorder Emerging Drugs

SYNP 101: Ceruvia Lifesciences

SYNP-101 is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms. Psilocybin has been shown to be safe when administered in a therapeutic setting. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Obsessive Compulsive Disorder.

Troriluzole: Biohaven Pharmaceuticals

Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters (i.e., EAAT2) located on glial cells that play a key role in clearing glutamate from the synapse. Glutamatergic dysfunction is implicated in the pathophysiology of a broad range of disorders including Amyotrophic Lateral Sclerosis (ALS), Spinocerebellar Ataxia (SCA), Alzheimer’s disease (AD), depression, Obsessive Compulsive Disorder (OCD), chronic pain, and a variety of cancers. The therapeutic potential of troriluzole is supported by clinical and translational research studies conducted with riluzole in a variety of indications. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Obsessive Compulsive Disorder.

Obsessive Compulsive Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Obsessive Compulsive Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Obsessive Compulsive Disorder

There are approx. 5+ key companies which are developing the therapies for Obsessive Compulsive Disorder. The companies which have their Obsessive Compulsive Disorder drug candidates in the most advanced stage, i.e. Phase III include, Biohaven Pharmaceuticals.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Obsessive Compulsive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obsessive Compulsive Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obsessive Compulsive Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obsessive Compulsive Disorder drugs.

Obsessive Compulsive Disorder Report Insights

• Obsessive Compulsive Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obsessive Compulsive Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obsessive Compulsive Disorder drugs?
• How many Obsessive Compulsive Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obsessive Compulsive Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obsessive Compulsive Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obsessive Compulsive Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ceruvia Lifesciences
• Biohaven Pharmaceuticals
• Octapharma

Key Products

• SYNP 101
• Troriluzole
• Panzyga